He was involved in cancer trials early in his career while at the EORTC. In recent years, he has worked on demonstrating the role of surrogate outcome measures in clinical research and the design of Phase I trials.
Other contributions to clinical trials methodology have been in randomization, oncology efficacy endpoints and data monitoring committees. Recently, he served as principal statistical advisor to the National Cancer Institute of France. In this position, he was able to advance the practice of oncology clinical trials on an international basis.
His early participation in the SCT was very helpful in giving the Society a presence among the European clinical trial community.
It was amazing to me that in 1991, as he was forming his own company, he had the time and energy to help to organize the first joint meeting of the SCT and ISCB in Brussels.